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Preeclampsia is a disorder characterised by vascular endothe-
lial dysfunction and vasospasm that occurs after 20 weeks of
gestation till 4–6 weeks postpartum. The global incidence of
preeclampsia has been estimated at 2–14% of all pregnancies.
Despite the advances made in the field, research is still
organised to clarify the possible molecular mechanisms or
predisposing factors of preeclampsia as well as the treatment
options for such a significant disorder. Papers were selected
on the basis of fundamental research ideas or reviews in the
field. This special issue is comprising of seven papers which
are focused on the better understanding of preeclapsia.
One of the papers deals with the correlation of pree-
clampsia with hypoxia, thrombosis, and inflammation. The
authors suggest that there is no accurate test for predicting
preeclampsia. The role of markers such as sFLT, sEng,
products of fetal and placental origin, markers of renal
or endothelial damage, or markers of oxidative stress is
presented by acting as secondary pathways to the pathophysi-
ological changes that precede the clinical onset of preeclamp-
sia. A combination of such markers is proposed in order to
increase the detection accuracy earlier in the pregnancy and
hopefully allow for more eﬀective prophylactic strategies.
Another paper sought to validate the use of urinary
podocyte (podocyturia) as a single diagnostic marker in
preeclampsia and in diﬀerentiating from other high-risk
pregnancy states with similar presentations. The researchers
discovered that podocyte loss is present not only in
preeclampsia but in other high-risk pregnancy states. In
addition, podocyturia was not found in amajority of patients
diagnosed with preeclampsia. So, they realized that their
findings had relatively low sensitivity and specificity, but they
proposed further research regarding the predictive value of
podocyturia in preeclampsia in larger studies.
The authors of one of the paper investigated whether
there is an association between angiotensin converting en-
zyme (ACE) insertion/deletion (I/D) polymorphism and
preeclampsia in 236 pregnant women. They showed that
there was significant diﬀerence in terms of genotype dis-
tribution between preeclampsia and controls, while it was
not found any diﬀerence in allele frequency for ACE I/D
polymorphism. A possible reason for the inconsistency could
be the genetic basis that caused diﬀerent susceptibilities
among diﬀerent populations.
Moreover, one paper is mentioning that both women and
children exposed to preeclampsia exhibit an adverse vascular
phenotype, a propensity to subclinical atherosclerosis, and
increased risk of adverse cardiac and vascular events in future
life. They suggest that further studies into the mechanisms
such as vascular dysfunction underlying the altered car-
diovascular phenotype might provide unique insight into
pathophysiological or molecular links between preeclampsia
and cardiovascular disease which may direct us to novel
treatment strategies for both conditions. Improvement in
vascular function is also proposed as a valuable intermediate
end point in studies aiming to reduce risk in this potentially
young and generally asymptomatic population before the
onset of clinical disease.
F. J. Valenzuela and colleagues have recently reviewed
some polymorphisms in important candidate genes involved
in diﬀerent pathogenic mechanisms related to preeclampsia
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and concluded that various studies in diﬀerent populations
have identified maternal polymorphisms associated with
preeclampsia through candidate gene approaches.
Luizon and colleagues with a Letter to the Editor add
to the paper of F. J. Valenzuela et al. by further referring
to candidate genes related to angiogenesis and endothelial
dysfunction in preclampsia performed in the Brazilian
population. Specifically, genotypes and haplotypes formed
by polymorphisms of VEGF, eNOS, and MMP-9, along with
an example of the interaction among these genes in the
prediction of preeclampsia provide additional information
with clinical relevance to its susceptibility.
An additional paper is a review of the molecular mech-
anisms which are contributing to the pathogenesis of pree-
clampsia. Altered angiogenic balance, systemic inflamma-
tion, dysregulation of Renin-Angiotensin system, and pla-
cental hypoxia or ischemia are mechanisms leading to
the pathogenesis of preeclampsia. However, it is unknown
whether the mechanisms act independently or have syner-
gistic eﬀects.
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